Cited by 16HIV/AIDS Research and InterventionsHIV, Drug Use, Sexual RiskHIV/AIDS drug development and treatment

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Patterns of PrEP continuation and coverage in the first year of use: a latent class analysis of a programmatic PrEP trial in Kenya

Open access

Abstract

Introduction: Effective PrEP use is critical for impact, but data are limited on common patterns of continuation and coverage among persons using PrEP in real‐world settings. Methods: Data are from the Partners Scale‐Up Project, a programmatic stepped‐wedge cluster‐randomized trial to integrate PrEP delivery in 25 Kenyan public health facilities conducted between February 2017 and December 2021. We evaluated PrEP continuation using visit attendance and pharmacy refill records, and computed medication possession ratio to define coverage during the first year of use. Latent class mixture models were used to identify and characterize membership to different PrEP continuation patterns. Multinomial logistic regression was used to examine the association between group trajectories and demographic and behaviour characteristics. Results: Overall, 4898 persons initiated PrEP, 54% (2640) were female, mean age was 33 years (standard deviation 11) and 84% (4092) had partners living with HIV. PrEP continuation was 57%, 44%, and 34% at 1, 3, and 6 months, respectively. Four unique trajectories of PrEP coverage were identified: (1) one‐fourth (1154) exhibited consistent high coverage throughout the year with 93%, 94%, 96%, and 67% continuing PrEP at months 1, 3, 6, and 12, respectively; (2) 13% (682) showed high coverage trajectory throughout 6 months but coverage rapidly declined thereafter (94%, 93%, 63%, and 10% continued at months 1, 3, 6, and 12, respectively); (3) 18.9% (918) exhibited moderate coverage trajectory with 91% of clients refilling PrEP at month 1 but nearly all dropped‐off thereafter (37%, 5%, and 4% continued at months 3, 6, and 12, respectively); and (4) 43.8% (2144) exhibited immediate discontinuation trajectory, in which nearly all did not have any subsequent PrEP refill. Overall, being female, older age, having partners living with HIV or of unknown HIV status were statistically associated with better PrEP continuation trajectories compared to the immediate discontinuation trajectory (p<0.05 for all). Conclusions: In this analysis of a real‐world PrEP implementation programme in Kenya, we found four distinct patterns of PrEP continuation, with one‐third of users exhibiting consistent high continuation throughout 12 months and two‐fifths with immediate discontinuation patterns. These data may help guide tailored interventions to support PrEP continuation in this setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jia2.26137

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The sample size calculations in Mugwanya et al. 2023 aimed to assess patterns of PrEP continuation and medication possession ratios during the first year of use.

    “The sample size calculations aimed to assess patterns of PrEP continuation and medication possession ratios during the first year of use.”

    From Applications and implementation considerations for stepped-wedge designs in sub-Saharan Africa: a systematic review (2026) · cites this paper as [71]

    The Methods > Analysis section (page unavailable) says the first-year analysis examined PrEP continuation and medication possession ratio. The paper does not say that sample size calculations were designed for that purpose; the Discussion instead describes the large study population as providing sufficient power to identify trajectories. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Mugwanya et al. 2023 used phased implementation, ensuring all clinics eventually received the intervention while enabling a rigorous evaluation of its effectiveness.

    “Phased implementation, ensuring all clinics eventually received the intervention while enabling a rigorous evaluation of its effectiveness”

    From Applications and implementation considerations for stepped-wedge designs in sub-Saharan Africa: a systematic review (2026) · cites this paper as [71]

    The Methods (Setting and population; page unavailable) describe a stepped-wedge cluster-randomized trial in 25 clinics, with PrEP delivery starting in stages. That supports phased implementation, but the paper does not explicitly say that every clinic eventually received the intervention or that this analysis evaluated the intervention’s effectiveness; its stated objective was to study PrEP continuation and coverage. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 32

  1. 10.1056/NEJMoa1108524 · DOI · Paper page
  2. 10.1016/S0140-6736(13)61127-7 · DOI · Paper page
  3. 10.1056/NEJMoa1011205 · DOI · Paper page
  4. 10.1056/NEJMoa1110711 · DOI · Paper page
  5. 10.1056/NEJMoa1202614 · DOI
  6. 10.1371/journal.pmed.1003670 · DOI
  7. 10.1002/jia2.25962 · DOI
  8. Celum CL, 2019, HIV pre‐exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery, J Int AIDS Soc, 22, 10.1002/jia2.25298 · DOI
  9. 10.1002/jia2.25636 · DOI
  10. 10.1016/S2352-3018(19)30335-2 · DOI
  11. 10.3389/frph.2021.683415 · DOI
  12. 10.1016/S2352-3018(19)30433-3 · DOI
  13. 10.1371/journal.pmed.1003492 · DOI
  14. 10.1097/QAD.0000000000000647 · DOI
  15. KMo Health.Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection in Kenya. 2016 Edition. Nairobi Kenya;2016.
  16. 10.1186/s13012-018-0809-7 · DOI · Paper page
  17. 10.1002/jia2.25799 · DOI
  18. 10.1037/1082-989X.7.2.147 · DOI · Paper page
  19. 10.1007/s10654-020-00615-6 · DOI
  20. 10.18637/jss.v078.i02 · DOI
  21. 10.1177/0011000016658097 · DOI
  22. 10.1097/QAI.0b013e31827e622d · DOI
  23. 10.21105/joss.01686 · DOI · Paper page
  24. 10.1080/13691058.2017.1367421 · DOI
  25. 10.1186/s43058-021-00228-4 · DOI
  26. Odoyo JB, 2019, Integrating PrEP into HIV care clinics could improve partner testing services and reinforce mutual support among couples: provider views from a PrEP implementation project in Kenya, J Int AIDS Soc, 22, 10.1002/jia2.25303 · DOI
  27. 10.1097/QAI.0000000000002625 · DOI
  28. 10.1007/s10461-018-2221-3 · DOI
  29. 10.1371/journal.pmed.1002099 · DOI
  30. 10.1002/jia2.25466 · DOI
  31. 10.1080/10705511.2016.1247646 · DOI · Paper page
  32. 10.1080/09540121.2020.1744507 · DOI

Cited by

Sorted by citations

Metadata

Authors
Mugwanya, K. K., Palayew, A., Schaafsma, T., Irungu, E. M., Bukusi, E., Mugo, N., Morton, J., Odoyo, J., Ngure, K., Baeten, J. M., & for the Partners Scale‐Up Project
Affiliations
  • University of Washington (US)
  • Kenya Medical Research Institute (KE)
Corresponding author
Mugwanya, Kenneth K.
Venue
Journal of the International AIDS Society
Publisher
Wiley
Published
2023-07
Volume
26
Issue
7
Pages
e26137-e26137
ISSN
1758-2652 (ISSN-L)
OpenAlex
W4383186793
Cited by
16
References
2
Citations by year
2026: 5 · 2025: 8 · 2024: 3
FWCI
3.31
Type
journal article
Language
en
Open access
Locations
  • Journal of the International AIDS Society (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute of Mental Health
  • Bill and Melinda Gates Foundation (OPP10556051)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
  • Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Keywords
pre-exposure prophylaxis, PrEP continuation, PrEP coverage, PrEP discontinuation, medication possession ratio, HIV prevention, HIV-positive partners, Kenya, public health facilities, latent class analysis, stepped-wedge cluster randomized trial
MeSH terms
Latent Class Analysis, Adult, Female, Humans, Kenya, Male, HIV Infections, Anti-HIV Agents, Pre-Exposure Prophylaxis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review